Latest news with #healthtech
National Post
3 hours ago
- Business
- National Post
Pramana Receives Health Canada Authorization for Digital Pathology Scanners
Article content CAMBRIDGE, Mass. — Pramana, an AI-enabled health tech company modernizing the pathology sector, today announced it has received Health Canada Medical Device Licenses for its flagship digital pathology scanners, the SpectralM and SpectralHT Cubiq systems. The approval authorizes Pramana to import, market, and sell its devices in Canada, expanding access to its advanced imaging and workflow solutions. Article content Health Canada authorization is required to commercialize Class II medical devices and affirms the product's safety, effectiveness, and quality. The approval opens the door for Pramana to support Canadian hospitals, pathology labs, and research institutions, helping modernize diagnostic workflows with scalable, AI-powered digital pathology tools. This recognition marks a critical step in Pramana's international expansion, building on its growing regulatory footprint. Article content 'Receiving Health Canada authorization is a major milestone in our commercialization strategy,' said Prasanth Perugupalli, Chief Product Officer at Pramana. 'It reflects the strength of our product development, quality, and regulatory readiness, and it opens the door to expanding access to our technology in a market known for strong clinical and academic institutions.' Article content Pramana's scanners are designed to digitize a wide range of pathology slides, producing high-resolution whole-slide images with automated quality control and AI-powered decision support. The platform supports both FFPE tissue and Liquid Based Cytology (LBC) samples prepared using methods such as the ThinPrep® Pap test (Hologic) and BD SurePath™ (Becton Dickinson). Unlike most digital pathology systems focused solely on anatomic pathology, Pramana expands digital workflows to include hematopathology, microbiology, and cytology, delivering flexibility across all major slide types. Article content 'Our research at the University of Toronto highlights the need for adaptable platforms that can manage these technical demands while still supporting routine histology and cytology workflows,' said Dr. Carlo Hojilla, Consultant Pathologist at the University of Toronto. 'Pramana's technology meets that standard, and its Health Canada authorization reflects both its clinical utility and the rigorous quality required for widespread adoption.' Article content Prior to receiving Health Canada authorization, Pramana secured Medical Device Single Audit Program (MDSAP) certification, a requirement that validated its quality management system and streamlined regulatory access in Canada, the United States, Brazil, Australia, and Japan, highlighting Pramana's commitment to modernizing digital pathology worldwide. Article content To discover how Pramana's whole-slide imaging solution can help healthcare organizations across Canada, visit Article content About Pramana, Inc. Article content Pramana is a health tech company transforming digital pathology with AI-powered imaging solutions that support seamless adoption across labs, health systems, and medical centers. Pramana's Spectral scanners deliver industry-leading image quality and unprecedented accuracy. Built-in AI algorithms and automated quality control streamline workflows, increase efficiency, and capture previously undetectable tissue features, empowering pathologists with the tools needed to improve clinical diagnostics and research. The company is headquartered in Cambridge, Mass. For more information, visit Article content Article content Article content Article content Article content Article content
Reuters
17 hours ago
- Business
- Reuters
Neuralink targets $1 billion revenue by 2031, Bloomberg News reports
July 23 (Reuters) - Elon Musk's brain implant company Neuralink aims to generate at least $1 billion in annual revenue by 2031, driven by plans to perform 20,000 surgeries per year, Bloomberg News reported on Wednesday, citing investor documents. The company aims to operate five large clinics within six years and offer three versions of its brain device, including Telepathy for communication between the brain and machines, Blindsight for restoring vision, and Deep for treating tremors and Parkinson's disease, according to the report. Neuralink did not immediately respond to a Reuters request for comment. The company expects regulatory approval for its Telepathy device by 2029, with plans to perform 2,000 surgeries annually and generate $100 million in revenue, the report said. By 2030, Neuralink anticipates launching Blindsight, expanding surgeries to 10,000 per year and generating over $500 million in revenue.
News.com.au
18 hours ago
- Business
- News.com.au
Why former Ramsay boss sees EMVision's portable stroke detection tech as game-changing
Former Ramsay boss and new EMVision director Carmel Monaghan believes its early stroke detection tech can transform lives Monaghan says EMVision is filling a gap in the market which could improve stroke outcomes Leading stroke centres in Australia and US taking part in pivotal trial for EMVision's first device, the emu bedside scanner EMVision's newest high-profile board director Carmel Monaghan believes the company's technology for early detection of stroke has the potential to "transform people's lives". Monaghan, who has joined the EMVision board as a non-executive director, stepped down this month from Ramsay Health Care (ASX:RHC) after five years as CEO of Ramsay Australia. Ramsay is Australia's largest private hospital operator and offers a range of multidisciplinary healthcare services along with extensive operations internationally. "EMVision is filling a gap in the market, and I've been impressed with the level of research undertaken over the last seven or eight years to bring rapid portable stroke sensing and imaging to point of care, which will really transform people's lives," Monaghan told Stockhead. "We know that time is brain in stroke diagnostics so getting quick, easy access to that neurodiagnostic solution can lead to a much-improved outcome." EMVision is currently undertaking a pivotal trial to support US Food and Drug (FDA) de novo (new device) clearance for its first commercial device – the emu bedside scanner – which is designed to rapidly diagnose stroke at the point-of-care. If granted clearance emu is anticipated to become the predicate device for its second device, First Responder, allowing an expedited 510(k) FDA pathway for the pre-hospital market. Leading stroke centres in Australia and the US are taking part in the trial including Mount Sinai Hospital in New York, Houston's Memorial Hermann-Texas Medical Center and the Mayo Clinic in Florida. EMV is also advancing a strategy to drive ongoing device innovation, refine its algorithms and generate data to support potential expansion of indications to include traumatic brain injury (TBI). This work forms part of EMVision's Continuous Innovation Study, which has received ethics approval to start scanning patients with suspected stroke or TBI at Brisbane's Princess Alexandra Hospital and Newcastle's John Hunter Hospital – both high-volume, comprehensive stroke and level-one trauma centres. Interest in advancing medical innovation Monaghan brings nearly 30 years of experience across hospital, corporate, and international roles at Ramsay. Before becoming CEO in 2020, she served as group chief of staff for Ramsay's global operations, gaining deep operational and strategic insight into the healthcare sector in both Australia and overseas. Monaghan also held the role of group head of marketing and public affairs, where she led the company's marketing, brand and communications strategy during a period of significant global expansion that saw Ramsay become one of the world's leading private healthcare operators. "I'm passionate about enhancing patient care through emphasising and embedding research and clinical trials into operations," Monaghan said. "I drove the expansion of clinical trials at Ramsay because I could see how this made a difference to clinical outcomes and people's lives. "At any one time, we had more than 250 clinical trials being undertaken at Ramsay facilities. "I am really interested in getting research to implementation and giving people hope and that has been a big passion of mine and what I love about medicine." Monaghan emphasised that whether it's drugs or devices, the goal is the same – to test and prove their impact, ultimately improving not just mortality rates but quality of life for people living with the burden of disease. "I've seen it with cancer drugs, robotic technology and that is what attracted me to EMVision. "It is health innovation with purpose and impact." World-renowned clinical team Monaghan noted EMVision's impressive technical, clinical and leadership team. She joins vastly experienced clinicians, medtech and business leaders on the board. The company's clinical advisory group also includes world-leading clinicians, working to address a strong clinical need. "EMVision have world-leading neurologists advising them along with huge luminary hospitals in the US like Mayo and Mt Sinnai, which are now scanning and enrolling patients,' she said, noting there are around 12.5 million strokes globally each year with 6.5 million dying annually. "It is a big burden of disease and one in four people globally over 25 will have a stroke in their lifetime, which has increased 50% over the past 17 years. "With stroke every minute counts and the outcome is heavily influenced by how quick the treatment is delivered. "Both the emu and First Responder will fill a gap where CT is just not practical and means the clinician who needs to make a quick treatment decision can do that effectively." She added that in the future there will also be interest in how the devices could be used to promptly diagnose TBI. "That is down the track, but it has great potential with studies underway at the John Hunter and the Princess Alexandra Hospital that will allow us to begin evaluating traumatic brain injury using our technology." Australia's global edge in health innovation Mongahan said Australia had long punched above its weight in health innovation, producing homegrown companies that have made a global impact. From hospitals to high-tech medical devices, the nation has cultivated a strong foundation in scientific research and clinical excellence – factors that continue to drive international success. She pointed to ASX-listed healthcare heavyweights such as Ramsay, blood products leader CSL (ASX:CSL), hearing implant pioneer Cochlear (ASX:COH), diagnostics and imaging specialist Sonic Healthcare (ASX:SHL), and sleep disorder device manufacturer ResMed (ASX:RMD) as world-class companies. "I have always admired how fantastic Australia is with healthcare and it's because we have such well-trained doctors and good scientific research," she said. "They've all been amazing, admirable companies which have been able to successfully transition overseas. "I think it's exciting how Australia has always performed so strongly in the health field, driven by world-class scientific research and highly trained medical professionals." At Stockhead, we tell it like it is. While EMVision is a Stockhead advertiser, it did not sponsor this article.
Yahoo
a day ago
- Business
- Yahoo
Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio
HOUSTON and SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million Series A financing round led by We Venture Capital and ClavystBio. The round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic's Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment. Proceeds will support expansion of Respiree's commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Respiree, with Founder and Chief Executive Officer Dr. Gurpreet Singh at Center 'The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,' said Dr. Gurpreet Singh, Founder and CEO of Respiree. 'What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up.' Respiree's innovative, augmented-AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform_Accelerate program, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers. Published as a pre-print in The Lancet, this flagship AI model significantly reduced false alarms while maintaining strong sensitivity — outperforming the positive predictive value (PPV) of EPIC's deterioration index by a factor of six (54.9% vs 8%). Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for its flagship AI model. The goal is to integrate the model into its platform, 1Bio™, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices and Respiree's proprietary, U.S.-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories. 'We are very proud to welcome Respiree to the We VC portfolio,' said Louise Warme, Head of We Venture Capital. 'Respiree stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration. Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team.' 'ClavystBio's investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights. This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,' said Anselm Tan, Digital Health & MedTech Lead, ClavystBio. Respiree's current solutions include: Scalable AI modules designed to be device-agnostic, platform independent and EHR-compatible, with increased precision to identify patient deterioration across patient touchpoints with low false alarms Pathway-management modules designed to automate delivery of standardized care pathways and requirements for nurses and patients to execute Centralized, EHR-agnostic platform connected to a broad range of EHR environments and medical device systems, consolidating continuous real-time analytics and data from multiple sources Connected wearables with configurable acquisition settings for a range of use-cases, capable of capturing a broad range of cardio-respiratory measures 'Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the Company in the convertible notes last year. We are incredibly encouraged by the commercialization of Respiree's products and services in tier-one markets and look forward to being part of Respiree's growth as it continues to transform patient care on a global scale. We very much welcome the new investors We VC, ClavystBio and Adaptive Capital and look forward to working together in Respiree's forward journey,' said Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund. Founded in Singapore, Respiree is now executing its global strategy to expand into new markets worldwide. Respiree's solutions are currently available in the U.S., Australia, and across Asia-Pacific (APAC). The company recently announced a partnership with Roche Diagnostics to launch pilot programs across the APAC region. The company has also established key international partnerships with leading global healthcare providers to support its expansion across both acute and home healthcare settings. A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships. Respiree plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand. About RespireeRespiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( About We Venture CapitalWe Venture Capital is a specialized fund, investing globally in diagnostics start-ups, as well as digital solutions and life science tools disrupting diagnostics. Launched 2023, We VC is focused on Series A investments, but also invest Seed and Series B. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare. About ClavystBio ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. ( About Greenwillow Capital Management The Oriza Greenwillow Technology Fund is a venture capital fund established jointly by Greenwillow Capital Management Pte Ltd, an MAS-licensed fund management company based in Singapore, and Oriza Holdings, an investment firm from China with assets under management exceeding RMB120 billion. The Fund invests in early-stage technology start-ups in Singapore and the fast-growing markets of Southeast Asia, with a primary focus on the smart cities and health-tech sectors. For more information, please visit Press ContactCammy DuongLifeSci Communicationscduong@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
3 days ago
- Business
- Forbes
Draya Michele Is Turning Criticism Into Capital—Starting With Clean Air
With a new investment in wellness tech and a fresh perspective on motherhood, Draya Michele steps confidently into a chapter defined by purpose, power and quiet reinvention. Draya Michele pictured in front of her latest wellness tech investment, Sereniby—a smart air care ... More system designed to support healthier environments for babies and young children. On a sunny afternoon in Santa Monica, California, I settled in for an NAD infusion and Normatec therapy—expecting a routine wellness reset—alongside entrepreneur, designer and now investor Draya Michele. Inside the sunlit sanctuary of Dripology—a sleek, minimalist wellness studio founded by ICU-trained nurse Hamed Afshari to bring medical-grade care into a luxury experience— what began as IV drips, compression boots and a few light laughs quickly unfolded into something far more intimate. The wellness advocate is entering a new era—one rooted in clarity, legacy and deeper intention. Known for her style, and decade-long success with Mint Swim, Draya is now channeling her energy into something far more personal: creating a safer, healthier world for the next generation, starting with her daughter. Watch Full Interview Here For Draya, wellness isn't just a treatment—it's a lifestyle that informs how she lives, parents and does business. And in doing so, she's reminding women—especially Black mothers—that they deserve to breathe deeply, build boldly and define success on their own terms. 'This season of my life feels different,' she tells me, as we settle in for our IV treatments. 'It's personal now. Every decision I make, I think about the impact it has on her.' A Partnership Rooted in Purpose Her newest move is a strategic investment and partnership with Sereniby, a wellness tech company redefining air care for babies and young children. The brand's flagship product—a smart, medical-grade air purifier—goes beyond filtration. It's built to support restful sleep, cleaner breathing environments and peace of mind for modern families. 'This isn't just another brand collab,' Draya clarifies. 'It's ownership. It's alignment. It's me investing in something I wish I had from day one as a mom.' Draya's connection to Sereniby didn't begin in a boardroom—it started in her daughter's nursery. During her pregnancy, she was remodeling her home and found herself surrounded by drywall, paint fumes and dust. 'I remember thinking, 'I can't be breathing this in while I'm growing a baby,'' Draya recalls. 'It made me hyper-aware of how overlooked air quality really is, especially for children.' Sereniby is a modern air purifier designed for nurseries, featuring medical-grade HEPA filtration, ... More whisper-quiet operation, and a gentle nightlight. Its sleek white body and wood-tone base blend seamlessly into any calming, baby-safe space. Sereniby stood out, thanks to a heartfelt note and family photos its founders sent Draya before the product even arrived. 'It wasn't just a product drop. It felt like something bigger,' Draya says. 'The purifier came days later and I was blown away. Not just by the design, but by the thoughtfulness behind it.' With hospital-trusted HEPA and carbon filtration, smart sensors that detect microscopic pollutants, and integrated white noise and light therapy features, Sereniby offered something that matched both her lifestyle and values. As a new mother again, Draya saw the product work firsthand—especially in supporting her daughter's sleep. 'She doesn't sleep easily, so anything that supports rest is gold to me. And if it also protects her health? That's not a luxury. That's essential.' Draya has faced public scrutiny in the past over her parenting style during her early years as a mother—a narrative she's since reclaimed by showing her evolution and deep commitment to growth. The entrepreneur's decision to invest wasn't just about the product—it was about the position. 'It's important to me that my daughter grows up seeing her mother not just as the face of something, but as someone who has a stake in it,' she says. 'I want her to see that we—Black women, Black mothers—belong at the forefront of wellness, parenting and innovation.' Draya Michele enjoying playtime with her daughter, with Sereniby in the background helping keep the ... More air fresh and clean. That positioning is key. As the wellness space grows, Draya's involvement signals a deeper shift: intentional representation at the ownership level. 'I've done collaborations. I've been the ambassador. This time, I wanted equity,' she says. Her investment also challenges the outdated notion that celebrity partnerships are purely transactional. 'This isn't PR. This is my daughter's air. This is our home. I use it every day. That's the difference," Draya expressed. Motherhood looks different this time around. Draya is juggling entrepreneurship, farm life (yes—more on that later), and raising a daughter who demands presence and patience. 'My sons were easy. My daughter? She's attached. She's loud. She's fire,' Draya says, laughing. 'I love it, but I've had to re-learn balance.' That means prioritizing routine, setting boundaries — especially on social media — and redefining what self-care looks like. 'I'm a post-and-go kind of woman now,' she says. 'I've limited who can comment on my posts because peace matters. If I didn't ask for your opinion, I don't need it.' It also means making smarter choices as a consumer and a mom. 'I used to be that person who bought the most expensive baby bottles—imported, hand-blown glass, $80 each,' she shares. 'Now? I'm an Evenflo six-pack for $10 kind of girl. They work just as well, and I don't cry when they break.' Draya Michele carries her daughter in a chest harness during a quiet moment together. Despite the glitz of entrepreneurship and the digital attention that follows her every move, Draya keeps her circle tight—and intentional. 'I'm really blessed to have a group of women around me that don't compete with each other,' she says. 'We all have our own lanes, and we show up for one another in real life.' Her core friend group—rooted in mutual respect, aligned values and zero performative energy—isn't just about vibes. It's protection. 'In this industry, especially as a Black woman, people project so much onto you. It helps to have friends who remind me who I am outside of social media, outside of work, outside of the noise.' And there's been plenty of that noise. Over the years, Draya has navigated harsh public judgment and unsolicited commentary about her personal life—most recently, when she shared an unpaid post about Sereniby during the LA fires, encouraging families to protect their indoor air quality. Santa Monica, California — Friday, June 6: Draya Michele sits down with Forbes contributor Corein ... More Carter for an interactive wellness interview at Dripology, where the two discuss motherhood, legacy, and Draya's newest investment in wellness tech. 'The comments were intense. People were like, 'Draya, people lost their homes—why are you talking about purifiers?' And I get that. But I wasn't speaking to those who experienced loss—I was speaking to the millions of others in LA breathing in that smoke,' she says. 'It came from a pure place. I wasn't paid. I just wanted to help.' Rather than clap back, she chose peace of mind. 'I've learned I don't have to explain everything. But I also won't let people twist my intentions. I believe in what I support.' To guard her peace, Draya has made a simple but profound adjustment: she limits who can comment on her social media posts. 'I post and go. I'm not here to be debated. This is my life, not a group chat,' she says. Though wellness is her latest move, Draya's swimwear brand Mint Swim remains a cultural staple. Known for putting Black and brown women at the forefront of its campaigns since the beginning, Mint Swim continues to champion diversity in a space that once overlooked it. Draya Michele stuns in her signature swimwear line, Mint Swim This past Earth Day, she introduced a limited capsule made from repurposed materials—using her boyfriend's old T-shirts to create new swimwear. 'Fabric waste is a real problem, and fashion contributes to it,' she says. 'I just wanted to do something that felt good and looked good.' With her usual eye for style and practicality, the drop was equal parts thoughtful and fashion-forward. 'It was fun, it was conscious, and it sold out fast,' she notes. 'We'll definitely do more.' In perhaps the most unexpected twist, Draya is now exploring homesteading. On her property, she has 16 chickens, three dogs, a cat and a full vegetable garden. 'I'm learning to grow what I eat. I'm obsessed with the process,' Draya expresses. The farm, like the purifier, represents something larger: autonomy. Peace. Slowness. 'This version of me isn't just about hustle. It's about health. It's about home. I want to show my kids what it looks like to build a full, beautiful life on your own terms.' In her garden, Draya Michele showcases her brand, Mint Swim. She's just as honest when reflecting on her early years as a founder. 'I used to be stubborn. I didn't ask for help. I made expensive mistakes,' she admitted. 'Now? I ask questions. I lean on my peers. You don't have to build alone.' Showing the Woman Behind the Brand In a world that often flattens public figures into brand extensions, Draya is committed to showing her whole self—even if it's unexpected. 'People have assumptions about me,' she admits. 'But the reality is, I'm a mom who recycles, a woman who gardens and someone who genuinely cares about this planet.' One of her quirks? She never litters. 'I'll carry trash in my purse all day before I throw it on the ground,' she says, laughing. 'And if you come to my house, you better write your name on your water bottle. We don't waste around here.' Draya Michele pictured in front of her latest wellness tech investment, Sereniby—a smart air care ... More system designed to support healthier environments for babies and young children. These small rituals—along with her larger moves in sustainability, wellness and conscious parenting—paint a fuller picture of Draya Michele: not just a personality, but a person. 'I'm not trying to be perfect. I'm trying to be real,' Draya adds. 'That's how I humanize myself—by showing up honestly. Whether it's on my farm, in the boardroom or online.' I want to keep showing people what's possible when you operate from intention, not just attention.' And for the little girl watching her every move, Draya's already paving the way. 'This isn't about being perfect. It's about being present. And I hope that everything I do shows my daughter she can build anything—and breathe deeply while doing it.' 'My biggest flex right now isn't a look or a moment,' Draya expresses. 'It's peace. It's alignment. It's knowing that every move I make reflects who I am and what I stand for.' 'I want my daughter to grow up watching me do this with grace, with grit, and with integrity,' Draya says. 'That's legacy. That's impact. That's the kind of woman I'm raising her to be.' And if this chapter is any indication, Draya Michele is just getting started.
